Health Care · Services-Medical Laboratories

PSNL Personalis, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 152775388 filings
Russell 2000

PSNL at a glance

Personalis, Inc. (PSNL, SEC CIK 1527753) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Personalis, Inc. (PSNL) reported revenue of $69.6 million (down 17.7% from FY2024) and a net loss of $81.3 million. Diluted EPS was -$0.91.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Personalis, Inc. (PSNL) shares worth $707.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Hall Christopher M on November 3, 2026 of 29,112 shares at $15.87 per share.
  • In the last 90 days, PSNL insiders reported 0 open-market purchases ($0) and 5 open-market sales ($729K) on Form 4, a net sale of $729K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$69.6M
−17.7% vs prior year
Insiders · 90 days
0 buys · 5 sells
Net −$729K
13F holders
28 funds
$707.6M · +1 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Pending Tempus merger, stockholder vote scheduled November 30, 2026, creates new completion and timing risk
  • Merger consideration, fixed exchange ratio 0.3356 below Tempus Floor Price $48.42, could value shares below $16.25
  • New tariff exposure, announced U.S. tariffs may raise laboratory costs that fixed-price contracts cannot immediately recover
  • Regulatory compliance, FDA could require medical-device authorization for LDTs, adding premarket review and ongoing obligations
  • Customer concentration, Moderna 13%, VA MVP 15%, and Merck 27% of nine-month 2026 revenue intensify renewal risk

Management Discussion & Analysis

  • Q3 revenue $25.6M, up 77% YoY from $14.5M, driven by pharma, clinical diagnostics and population sequencing
  • Operating margin -138.8% vs -160.7% YoY, calculated from operating losses of $35.5M and $23.3M
  • Best segment: clinical diagnostics $4.4M, up 1,039% YoY; worst: enterprise sales, down 99%
  • Cash and investments $190.6M vs $240.0M at year-end; nine-month operating cash use $75.3M
  • 2026 capital expenditures expected at $10.0M-$12.0M; headwinds include reimbursement-related testing costs and Merger uncertainty

AI summary of the PSNL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Personalis announced financial results for the quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for revenue, profitability, cash position and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $25.6M, up from $14.5M, driven by clinical testing, pharma services and population sequencing
  • Clinical volume 13,157 tests versus 4,388, with clinical revenue rising to $4.4M from $0.4M
Filed Oct 6, 2026Full analysis →

Item 8.01: Other Events

  • HSR antitrust waiting period expired October 2, 2026, removing a major regulatory closing condition
  • Tempus acquisition still requires Personalis stockholder approval and satisfaction or waiver of remaining conditions
Filed Aug 20, 2026Full analysis →

Item 8.01: Other Events

  • New VA MVP task order valued up to $18.3 million, effective September 30, 2026
  • Cumulative VA MVP task-order value increased to approximately $243.3 million

AI summaries of PSNL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PSNL

Don't miss the next PSNL filing

  • Alerts as it files. A push when PSNL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PSNL, by share count.
  • Ask anything. An AI agent that reads every PSNL filing and answers with sources.

PSNL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Hall Christopher MSellNov 3, 2026$15.87
Chen RichardSellSep 18, 2026$16.22
Moore Stephen MichaelSellSep 18, 2026$16.22
Tachibana AaronSellSep 18, 2026$16.22
Hall Christopher MSellSep 18, 2026$16.22
Chen RichardMJul 15, 2026$2.44
Chen RichardSellJul 15, 2026$15.15
Chen RichardMJul 15, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$84.6M$69.6M
Operating Income-$109.9M-$68.3M-$88.1M
Net Income-$108.3M-$81.3M-$81.3M
Op. Margin--80.7%-126.4%
Net Margin--96.1%-116.7%
Balance Sheet
Total Assets-$270.3M$334.2M
Equity-$203.0M$261.2M
ROE--40.0%-31.1%
Per Share
EPS$-2.25$-1.37$-0.91
Cash Flow
Operating CF--$45.1M-$74.9M
CapEx$10.9M$1.6M$4.5M

Source: XBRL data in Personalis, Inc. (PSNL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PSNL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PSNL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$707.6M
Q2 202627$645.0M
Q1 202626$287.7M
Q4 202525$333.0M
Q3 202524$236.5M
Q2 202524$229.7M
Q1 202521$93.6M
Q4 202416$149.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 191 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PSNL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 4, 2026--
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
8-KOct 6, 2026Analysis-
4Sep 22, 2026--
4Sep 22, 2026--
4Sep 22, 2026--
4Sep 22, 2026--
8-KAug 20, 2026Analysis-
8-KAug 4, 2026Analysis-
10-QAug 4, 2026Analysis
SC 13GJul 29, 2026-
8-KJul 20, 2026Analysis-
8-KJul 20, 2026Analysis-
4Jul 15, 2026--
4Jul 9, 2026--
4Jun 29, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 11, 2026--
4Jun 5, 2026-
4May 29, 2026-
4May 29, 2026-
8-KMay 20, 2026Analysis
4May 14, 2026-

Related Health Care companies

All Health Care →

PSNL SEC filings: frequently asked questions

Are PSNL insiders buying or selling?

In the last 90 days, Personalis, Inc. (PSNL) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $728,924 by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold PSNL stock?

As of September 30, 2026, the largest Personalis, Inc. (PSNL) holders among the 13F filers tracked by SignalX were Merck & Co. ($228.7 million), ARK Investment Management ($115.9 million), BlackRock ($112.9 million), Vanguard Capital Management LLC ($53.2 million), State Street Corp ($25.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PSNL's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Personalis, Inc. (PSNL) reported revenue of $69.6 million (down 17.7% from FY2024) and a net loss of $81.3 million. Diluted EPS was -$0.91. The figures come from the XBRL data in the 10-K.

What did PSNL report in its latest 8-K?

Personalis, Inc. (PSNL) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Personalis announced financial results for the quarter ended September 30, 2026.

What are the latest PSNL SEC filings?

Personalis, Inc. (PSNL) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 4, 2026.

What is PSNL's SEC CIK number?

Personalis, Inc. (PSNL)'s SEC Central Index Key (CIK) is 1527753. EDGAR lists every PSNL filing under that number.

Ask anything about PSNL

The research agent reads PSNL's filings, financials, insider trades and 13F holders, then answers with sources.